BAX
BuySecond WindFLAGBaxter International Inc. · Healthcare · United States · $13.5B · Avg Vol: $131M/d
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
Insufficient evidence for a screen-pass. Baxter International Inc.: fails the quant gate on quality (Q42/V55/M70; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT BAXTER INTERNATIONAL INC.
Read
Baxter International Inc. is a global healthcare company providing a broad portfolio of essential healthcare products, including kidney dialysis, sterile IV solutions, infusion systems, and surgical equipment. The company benefits from high switching costs for critical medical devices and a global installed base within hospitals and clinics. Baxter is a significant player in kidney care and hospital products, offering life-sustaining therapies and essential medical technologies worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.1B | 10.4B | 10.6B | 11.2B | 3.8% | 11.5B | 11.6B | 11.9B | 2.7% |
| EPS | -4.83 | 5.25 | -1.27 | -1.87 | — | -1.88 | — | — | — |
| Shares | 504.4M | 507.6M | 510.9M | 514.3M | +2.0% | 517.0M | — | — | — |
| Debt | 17.2B | 14.1B | 13.4B | 9.8B | -17.2% | 9.7B | — | — | — |
| Equity | 5.8B | 8.4B | 7.0B | 6.1B | 1.7% | — | — | — | — |
| Op CF | 1.2B | 1.7B | 1.0B | 845.0M | -11.3% | 1.3B | — | — | — |
| Inv CF | -931.0M | 3.2B | -626.0M | 2.8B | — | — | — | — | — |
| Fin CF | -1.4B | -3.5B | -1.1B | -4.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BAX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BAX | Baxter International Inc.(you) | $13.5B | 73 | Buy |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| RGEN | Repligen Corporation | $9.9B | 50 | Hold |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.